TABLE 2.

Outcomes.

Safety outcomes	Placebo	Desmopressin
Bleeding up to 24 h post treatment	N = 22	N = 19 a
New active bleeding	1 (4.5) a	0 (0.0)

Blood products received up to 24 h post treatment	N = 22	N = 18 b , c
Any blood component transfused	5 (25.0)	5 (27.8)
Any red cell transfusion	4 (18.2)	3 (15.8)
Any platelet transfusion	4 (18.2)	3 (15.8)
Any plasma transfusion	0	0
Any cryoprecipitate transfusion	0	0

Serious adverse events (SAE) up to Day 28	N = 22	N = 21
All SAEs	34	23
Participants with at least one SAE	13 (59.1)	11 (52.4)
Thromboembolic events d	4 (18.2)	1 (5.3)
Deaths	6 (27.3)	8 (38.1)

Note: Data presented as n (%).

^a Minor bleeding from a central venous catheter insertion site.

^b The participants allocated to desmopressin arm and who withdrew before the intervention are excluded.

^c No data available for one patient.

^d Thromboembolic events: In the desmopressin arm, there was one myocardial infarction (Day 1 after treatment). In the placebo arm, there was one myocardial infarction (Day 7), two deep vein thromboses (Day 9 and Day 20) and one ischaemic stroke (Day 6).